Previous experiments about the impact of vector-based expression on the response to standard therapeutics had demonstrated that the reactivation of DAPK1 sensitizes ovarian cancer cells to Paclitaxel and Cisplatin (Figure 6 and Figure 7). This evidence concerns the gene DAPK1 and ovarian carcinoma.